Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. It uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The Company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Company Growth (employees)
West Lafayette, US
Size (employees)
76 (est)
Endocyte was founded in 1995 and is headquartered in West Lafayette, US

Key People at Endocyte

Mike A. Sherman

Mike A. Sherman

President & CEO

Endocyte Office Locations

Endocyte has offices in West Lafayette and Indianapolis
West Lafayette, US (HQ)
3000 Kent Avenue
Indianapolis, US
8910 Purdue Rd, Suite 250

Endocyte Data and Metrics

Endocyte Financial Metrics

Endocyte's revenue was reported to be $12.5 k in Q1, 2017

Revenue (Q1, 2017)

12.5 k

Net income (Q1, 2017)

(11.5 m)

EBIT (Q1, 2017)

(11.7 m)

Market capitalization (21-Sep-2017)

58.7 m

Cash (31-Dec-2016)

31.2 m
Endocyte's current market capitalization is $58.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


64.9 m70.4 m70 k70 k

Revenue growth, %


R&D expense

27.5 m

General and administrative expense

17.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


12.5 k12.5 k12.5 k32.5 k12.5 k

R&D expense

19 m5.7 m6.6 m6.7 m6.6 m6.5 m6.8 m6 m8 m

General and administrative expense

8 m4 m4.4 m4.1 m3.8 m3.8 m7.4 m3 m3.7 m

Operating expense total

27 m9.7 m11 m10.8 m10.4 m10.4 m14.2 m9 m11.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


52.8 m45.5 m15.4 m31.2 m

Current Assets

133.3 m127 m174.9 m140.3 m


3.8 m4 m3.4 m3.2 m

Total Assets

162.9 m212.8 m178.4 m143.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016


31.6 m48.6 m29.2 m28 m31 m40.2 m26.6 m34.7 m

Current Assets

128.7 m134.3 m162.2 m175 m173.7 m164.8 m155.8 m148.5 m


4.2 m4.1 m3.8 m3.7 m3.6 m3.6 m3.5 m3.4 m

Total Assets

230.9 m221 m202.6 m194 m185.6 m168.5 m159.4 m152 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)

Depreciation and Amortization

674.7 k857.1 k886.7 k

Accounts Payable

(386.2 k)(3.7 m)(60.7 k)1.4 m

Cash From Operating Activities

(51.1 m)(42.2 m)(32.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

22.4 m(5.7 m)(10.9 m)(10.6 m)(10 m)(10.2 m)(14 m)(8.7 m)(11.5 m)

Accounts Payable

3.5 m1.1 m1.6 m1.5 m956.9 k1.2 m1.4 m1.5 m1.5 m
USDY, 2017


Show all financial metrics

Endocyte Market Value History

Traffic Overview of Endocyte

Endocyte Company Life and Culture

You may also be interested in